ALLR vs GS · P/E 0.0, rev $25.0K vs P/E 20, rev $37.56B
Allarity Therapeutics Inc (ALLR) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Allarity Therapeutics Inc (ALLR) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported ALLR revenue for 2026-06-30 was $25.0K. Net income was -$6.2M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. ALLR currently screens at market cap $15.1M and trailing P/E 0.0.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
ALLR currently screens at market cap $15.1M and trailing P/E 0.0. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the ALLR and GS stock pages for the full models.
Not investment advice.